COUNTERPOINT B-1

Jacqueline Kim Blechinger founded Counterpoint to address the unique needs of biotechs undergoing financial challenges. She brings over twenty years of global multi-product investments, transactions, and risk management expertise across early-to-late-stage life science private and public companies.  Her expertise is in working directly with stakeholders and leading complex restructuring, recapitalization transactions, and managing board environments.  Jacqueline places a strong focus on collaborating with investors and their portfolio companies.

Prior to founding Counterpoint, Ms. Blechinger played a formative role at GE Capital, where she helped build its life sciences financial services risk management business.  This included underwriting, portfolio management, documentation, and loss mitigation and recovery capabilities.  She instituted strategic fund investments, negotiated proprietary deal flow relationships, and led groundbreaking global, multi-product transactions.  For over a decade, Ms. Blechinger closed and managed more than 80 transactions across debt and equity through various market cycles.  Previously, at Bristol-Myers Squibb in Corporate Business Development, she closed worldwide transactions in three therapeutic areas exceeding $1B.  Ms. Blechinger also worked at The CIT Group in Ventures and Equity Investments, where she co-invested in early-to-mid-stage life science and device investments, as well as middle-market mezzanine and equity-like investments.  She began her career as a corporate finance associate engaged in private placement, M&A, IPO, and secondary assignments at the NYC boutique Prime Charter Ltd., Series 7 and 63 licensed. 

Jacqueline holds an AB from Dartmouth College, an MFA from Cornell University School of Architecture, Art, and Planning, is a Skowhegan alumna, and has an MBA from Columbia Business School.  Jacqueline grew up in New York City and graduated from Stuyvesant High School.